MARKETS
Analyst Actions

Jefferies Initiates Coverage On Vicore Pharma Holding with Buy Rating, Announces Price Target of $25

Oct 9, 2026 · 02:49 PM ET· updated 2d ago

Jefferies analyst Faisal Khurshid initiates coverage on Vicore Pharma Holding (NASDAQ:VCRE) with a Buy rating and announces Price Target of $25.

Share
Why It Matters

A big investment company thinks Vicore Pharma is worth buying now. They believe the stock could go up to $25 in value.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.